<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406833</url>
  </required_header>
  <id_info>
    <org_study_id>ISTH-01-111</org_study_id>
    <secondary_id>2014-004985-74</secondary_id>
    <nct_id>NCT02406833</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isarna Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isarna Therapeutics GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2,
      to glaucoma filtration surgery (trabeculectomy). The treatment aims at improving the surgery
      outcome by prevention of excessive scarring and trabecular meshwork transformation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The transforming growth factor beta (TGF-β) is known to play a key role in glaucoma.
      Increased levels of TGF-β2 in the eye have been linked to trabecular meshwork transformation,
      increased intraocular pressure and direct optic nerve damage.

      Trabeculectomy is the standard surgical intervention to reduce intraocular pressure in
      subjects no longer sufficiently responding to pressure-lowering medications. Scarring of the
      surgically opened canal (bleb) often abolishes the effect of trabeculectomy (despite the
      intraoperative use of Mitomycin C to prevent this). TGF-β2 has been described to play a
      distinct role in the fibrotic process of bleb closure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by clinical monitoring and reporting of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interventions post trabeculectomy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>TGF-β2 antisense oligonucleotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses
Post-Study Follow-up: until 1 year after administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TGF-β2 antisense oligonucleotide</intervention_name>
    <description>intravitreal injection</description>
    <arm_group_label>TGF-β2 antisense oligonucleotide</arm_group_label>
    <other_name>ISTH0036</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control</description>
    <arm_group_label>TGF-β2 antisense oligonucleotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject scheduled for trabeculectomy with Mitomycin C

          -  Subject no longer tolerating or benefitting from pharmacologic treatment of glaucoma

        Exclusion Criteria:

          -  History of relevant ocular trauma &lt; 6 months or ocular infection/inflammation &lt; 3
             months

          -  severe central visual field loss within 6 months unrelated to glaucoma

          -  pregnant or nursing women or subjects not using adequate contraception

          -  history or evidence of any other clinically significant disorder, condition or disease
             that would pose a risk to subject safety or interfere with study evaluations,
             procedures or interpretation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Fettes, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Isarna Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Magdeburg, Ophthalmology</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Johannes-Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen, Center of Ophthalmology</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

